[Xerostomia and asalia due to psychopharmacologic therapy and their treatment with TPMP (trithioparamethoxyphenylpropen)].
D000840:Anisoles / Q000494:pharmacology / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D006571:Heterocyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D010300:Parkinson Disease / Q000188:drug therapy; D010306:Parotid Gland / Q000503:physiopathology; D011188:Potassium / Q000032:analysis; D011877:Radionuclide Imaging; D012463:Saliva / Q000032:analysis; D012472:Salivation / Q000187:drug effects*; D012559:Schizophrenia / Q000188:drug therapy; D013667:Technetium; D013871:Thiones / Q000494:pharmacology / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000009:adverse effects; D014987:Xerostomia / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology
D000840:Anisoles; D006571:Heterocyclic Compounds; D013871:Thiones; D014149:Tranquilizing Agents; D013667:Technetium; D011188:Potassium
Xerostomie und Asialie unter Psychopharmaka und deren Beeinflussung durch TPMP (Trithioparamethoxyphenylpropen)